Search results
New PET agent provides same-day imaging for clear cell renal cell carcinoma patients
Medical Xpress· 11 hours agoA novel investigational PET imaging agent can rapidly and accurately visualize lesions in clear cell renal cell cancer (ccRCC) patients ...
AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 4 minutes agoIn Q1 2024, no additional molecules advanced into the clinic, and we maintained the cumulative total...
Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients - British...
Nature· 4 days agoTregs trafficking is controlled by CXCR4. In Renal Cell Carcinoma (RCC), the effect of the new CXCR4 antagonist, R54, was explored in ...
Massive study identifies new biomarkers for renal cancer subtypes, improving diagnosis and—...
Newswise· 2 days agoA new study led by University of Michigan Health Rogel Cancer Center researchers identifies novel...
Fighting Cancer: A Basic Guide To Checkpoint Inhibitors
Forbes· 2 days agoThis article is part of an ongoing series on novel cancer advances, including immunotherapies such...
Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short
Zacks via Yahoo Finance· 7 days agoCabometyx (cabozantinib) generated revenues of $376.4 million, which missed the Zacks Consensus...
Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 2 days agoInvestors' focus will likely be on Iovance's (IOVA) progress with its ongoing commercial launch for...
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
Zacks via Yahoo Finance· 6 days agoModerna/Merck also started two separate mid-stage studies in renal cell carcinoma and...
CD70 Antibodies CD70 Targeting Therapies Clinical Trials Market Opportunity Insight
Benzinga· 7 days agoDelhi, May 01, 2024 (GLOBE NEWSWIRE) -- Global CD70 Targeting Therapies Market Opportunity & Clinical Trials Insight 2024 Report Highlights: CD70 Targeting Therapies In Clinical Trials: > 20 TherapiesCD 70
Exelixis (NASDAQ:EXEL) Earns “Outperform” Rating from William Blair
ETF DAILY NEWS· 4 days agoWilliam Blair reaffirmed their outperform rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a report published on Wednesday, RTT News reports. Barclays lowered Exelixis from an overweight ...